DE602004019653D1 - Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält - Google Patents

Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält

Info

Publication number
DE602004019653D1
DE602004019653D1 DE602004019653T DE602004019653T DE602004019653D1 DE 602004019653 D1 DE602004019653 D1 DE 602004019653D1 DE 602004019653 T DE602004019653 T DE 602004019653T DE 602004019653 T DE602004019653 T DE 602004019653T DE 602004019653 D1 DE602004019653 D1 DE 602004019653D1
Authority
DE
Germany
Prior art keywords
drug
dosage form
agent component
adverse
barrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004019653T
Other languages
German (de)
English (en)
Inventor
John R Hart
Steven C Anderson
Melissa A Vanblaricom
Ellen R Bosl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of DE602004019653D1 publication Critical patent/DE602004019653D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004019653T 2003-04-30 2004-03-23 Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält Expired - Lifetime DE602004019653D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46724303P 2003-04-30 2003-04-30
US10/744,966 US20040219195A1 (en) 2003-04-30 2003-12-23 Abuse-resistant transdermal dosage form
PCT/US2004/008856 WO2004098568A2 (en) 2003-04-30 2004-03-23 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer

Publications (1)

Publication Number Publication Date
DE602004019653D1 true DE602004019653D1 (de) 2009-04-09

Family

ID=33313652

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004019653T Expired - Lifetime DE602004019653D1 (de) 2003-04-30 2004-03-23 Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält

Country Status (9)

Country Link
US (2) US20040219195A1 (https=)
EP (1) EP1651196B1 (https=)
JP (2) JP2006525315A (https=)
AT (1) ATE423551T1 (https=)
AU (2) AU2004237579A1 (https=)
CA (1) CA2523709A1 (https=)
DE (1) DE602004019653D1 (https=)
ES (1) ES2322154T3 (https=)
WO (1) WO2004098568A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
CN101232875B (zh) 2005-06-10 2014-06-25 3M创新有限公司 处理粘合层叠片片段的方法
BRPI0619806A2 (pt) * 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
DE102006025282A1 (de) 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
WO2008073576A1 (en) * 2006-12-08 2008-06-19 Alcon, Inc. Drug delivery device
EP2259780A2 (en) 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
JP5386205B2 (ja) * 2009-03-19 2014-01-15 リンテック株式会社 経皮吸収型貼付剤
JP2013524275A (ja) * 2010-04-03 2013-06-17 ドシ，プラフル 薬剤を含む医療機器、その製造方法とその使用方法
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2013148506A1 (en) * 2012-03-30 2013-10-03 3M Innovative Properties Company Urea-based and urethane-based pressure sensitive adhesive blends
US9950106B2 (en) 2012-12-05 2018-04-24 Cook Medical Technologies Llc Antimicrobial barrier device
CN115444659A (zh) * 2014-01-22 2022-12-09 4P治疗公司 滥用和误用制止透皮系统
WO2016099986A2 (en) 2014-12-18 2016-06-23 3M Innovative Properties Company Methods of handling adhesive laminate patches
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
CN107613853A (zh) 2015-01-23 2018-01-19 马尔西奥·马克·阿布雷乌 用于皮肤处理的设备和方法
CN110470607B (zh) * 2018-05-09 2021-12-07 江苏集萃智能液晶科技有限公司 一种检测混合溶液中亲水性有机溶剂含量的方法
WO2020008370A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1602344A (en) * 1924-01-09 1926-10-05 Eagle Peter Medicating compress
US2807262A (en) * 1952-12-10 1957-09-24 Robert B Lew Perforated plastic adhesive tape bandage
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4539256A (en) * 1982-09-09 1985-09-03 Minnesota Mining And Manufacturing Co. Microporous sheet material, method of making and articles made therewith
US4693776A (en) * 1985-05-16 1987-09-15 Minnesota Mining And Manufacturing Company Macromer reinforced pressure sensitive skin adhesive
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
JPH0538010Y2 (https=) * 1987-03-17 1993-09-27
DE3722775A1 (de) * 1987-07-09 1989-01-19 Lohmann Therapie Syst Lts Transdermales therapeutisches system
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5176917A (en) * 1989-03-15 1993-01-05 Lts Lohmann Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
CA2173855C (en) * 1993-10-29 2007-06-26 Mieczyslaw H. Mazurek Pressure-sensitive adhesives having microstructured surfaces
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
WO1997004835A1 (de) * 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US5840327A (en) * 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
ATE364380T1 (de) * 2001-03-16 2007-07-15 Alza Corp Transdermales pflaster zur verabreichung von fentanyl
SI2062573T1 (sl) * 2001-05-01 2012-02-29 Euro Celtique Sa Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid
TW200404581A (en) * 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
DE102004038179A1 (de) * 2004-08-06 2006-03-16 Daimlerchrysler Ag Verfahren zur Herstellung einer thermisch beschichteten Zylinderlauffläche mit einer Einfuhrfase

Also Published As

Publication number Publication date
JP2006525315A (ja) 2006-11-09
ES2322154T3 (es) 2009-06-17
US20100068249A1 (en) 2010-03-18
JP2012140453A (ja) 2012-07-26
AU2010257440B2 (en) 2011-11-24
AU2004237579A1 (en) 2004-11-18
WO2004098568A2 (en) 2004-11-18
ATE423551T1 (de) 2009-03-15
US20040219195A1 (en) 2004-11-04
EP1651196B1 (en) 2009-02-25
CA2523709A1 (en) 2004-11-18
EP1651196A2 (en) 2006-05-03
WO2004098568A3 (en) 2005-02-03
AU2010257440A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
DE602004019653D1 (de) Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält
CY1109070T1 (el) Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DK1521593T3 (da) Transdermale botulinumtoksinforbindelser
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
DK1178783T3 (da) Indretning og anvendelse til forögelse af den transdermale permeation af lægemidler
JP2006525315A5 (https=)
RU2004103746A (ru) Фармацевтическая композиция для лечения интерстициального цистита
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
AR038858A1 (es) Combinacion
NO20062234L (no) Transdemisk,farmasoytisk spray-formulering omfattende en VP/UA kopolymer og en ikke-vandig vehikkel
WO2005117871A3 (en) Pharmaceutical compositions for the treatment of pruritus
Cao et al. Efficacy of a topical proteinase-activated receptor-2 inhibitor on cowhage-induced pruritus: a randomized placebo-controlled double-blind study.
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
BR0104586A (pt) Método para tratamento de neurodegeneração
BRPI0518554A2 (pt) uso de um inibidor de pde3
DE50210037D1 (de) VERWENDUNG VON WIRKSTOFFEN MIT õ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG
ATE424896T1 (de) Entpigmentisierende bzw. aufhellende kosmetikzusammensetzung, die mindestens ein oxazolin als wirkstoff umfasst
EA200501514A1 (ru) Сочетания действующих веществ и способы лечения злоупотребления алкоголем

Legal Events

Date Code Title Description
8364 No opposition during term of opposition